Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy

被引:0
|
作者
Pengchao Zhao
Xianfeng Xia
Xiayi Xu
Kevin Kai Chung Leung
Aliza Rai
Yingrui Deng
Boguang Yang
Huasheng Lai
Xin Peng
Peng Shi
Honglu Zhang
Philip Wai Yan Chiu
Liming Bian
机构
[1] The Chinese University of Hong Kong,Department of Biomedical Engineering
[2] Sun Yat-sen University Cancer Center,Department of Endoscopy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[3] The Chinese University of Hong Kong,Chow Yuk Ho Technology Centre for Innovative Medicine
[4] The Chinese University of Hong Kong,Department of Surgery, Institute of Digestive Disease, State Key Laboratory of Digestive Disease
[5] South China University of Technology,School of Biomedical Sciences and Engineering, Guangzhou International Campus
[6] South China University of Technology,National Engineering Research Center for Tissue Restoration and Reconstruction
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
A key challenge for the effective treatment of gastrointestinal diseases including inflammatory bowel disease is to develop an orally administered drug delivery system capable of prolonged retention in the gastrointestinal tract. Herein we report a bioadhesive liquid coacervate based on hydrogen bonding-driven nanoparticle assembly. Free from electrostatic interactions, our fluid nanoparticle-assembled coacervate demonstrates significant pH- and salt-independent structural stability and forms a physically adhesive coating on a large surface area of intestinal tract with an extended residence time of more than 2 days to mediate the sustained release of preloaded water-soluble small molecule drugs in vivo. The orally administered drug-laden nanoparticle-assembled coacervate significantly mitigates the symptoms of inflammatory bowel disease, restores the diversity of gut microbiota, reduces systemic drug exposure, and improves the therapeutic efficacy in a rat acute colitis model compared with the oral administration of the same amount of drug in solution form. We suggest that the nanoparticle-assembled coacervate provides a promising drug delivery platform for management and treatment of numerous gastrointestinal diseases where controlled drug release with extended residence time is desired.
引用
收藏
相关论文
共 31 条
  • [21] The value of gastrointestinal ultrasound in predicting sonographic remission to vedolizumab: A step towards individualized biological therapy of inflammatory bowel disease
    Hean, R.
    Su, H.
    Taylor, K.
    Rosella, G.
    Ward, M.
    Swaine, A.
    Sparrow, M.
    Martin, C.
    Gibson, P.
    Friedman, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 157 - 158
  • [22] Changes in intestinal microbiota and biochemical parameters in patients with inflammatory bowel disease and irritable bowel syndrome induced by the prolonged addition of soluble fibers to usual drug therapy
    Watanabe, Hideo
    Inoue, Takahisa
    Miyamoto, Licht
    Ono, Yoshito
    Matsumoto, Kinya
    Takeda, Masanori
    Tsuchiya, Koichiro
    JOURNAL OF MEDICAL INVESTIGATION, 2024, 71 (1-2): : 121 - 128
  • [23] REDUCED MORTALITY RATES WITH ANTI-TUMOR NECROSIS FACTOR ALPHA DIRECTED THERAPY WHEN COMPARED TO PROLONGED CORTICOSTEROID THERAPY FOR INFLAMMATORY BOWEL DISEASE
    Lewis, James D.
    Scott, Frank I.
    Brensinger, Colleen M.
    Roy, Jason A.
    Osterman, Mark T.
    Mamtani, Ronac
    Chen, Lang
    Yun, Huifeng
    Xie, Fenglong
    Curtis, Jeffrey R.
    GASTROENTEROLOGY, 2017, 152 (05) : S64 - S65
  • [24] Meaningful Symptoms of Immune Checkpoint Inhibitor Therapy-Related Gastrointestinal Adverse Events in Patients With Inflammatory Bowel Disease Reply
    Abu-Sbeih, Hamzah
    Faleck, David M.
    Dougan, Michael
    Wang, Yinghong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1749 - +
  • [25] Multiplex Gastrointestinal Pathogen Panel Testing is Associated with Higher Rates of Inflammatory Bowel Disease Therapy Escalation in Patients Hospitalised with Flare
    Verma, A.
    Axelrad, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S602 - S604
  • [26] Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease
    Guaitoli, Giorgia
    Baldessari, Cinzia
    Tomasello, Chiara
    Barbieri, Fausto
    Cascinu, Stefano
    Bertolini, Federica
    Cesinaro, Anna Maria
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E152 - E153
  • [27] 5-AMINOSALICYLIC ACID (5-ASA) RETENTION ENEMATA FOR LONG-TERM THERAPY OF INFLAMMATORY BOWEL-DISEASE (IBD)
    WYMAN, JB
    NUNEZ, JF
    PARENT, K
    NORFLEET, RG
    KIRCHNER, JP
    RYAN, ME
    RHODES, RA
    GASTROENTEROLOGY, 1985, 88 (05) : 1636 - 1636
  • [28] Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi)
    Ciccocioppo, R.
    Baumgart, D. C.
    Dos Santos, C. C.
    Galipeau, J.
    Klersy, C.
    Orlando, G.
    CYTOTHERAPY, 2019, 21 (08) : 824 - 839
  • [29] Postoperative course of laparoscopic subtotal colectomy is affected by prolonged preoperative anti-TNF therapy in patients with acute colitis complicating inflammatory bowel disease
    Monsinjon, Marie
    Mege, Diane
    Maggiori, Leon
    Treton, Xavier
    Bouhnik, Yoram
    Panis, Yves
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2017, 32 (10) : 1499 - 1502
  • [30] Postoperative course of laparoscopic subtotal colectomy is affected by prolonged preoperative anti-TNF therapy in patients with acute colitis complicating inflammatory bowel disease
    Marie Monsinjon
    Diane Mege
    Léon Maggiori
    Xavier Treton
    Yoram Bouhnik
    Yves Panis
    International Journal of Colorectal Disease, 2017, 32 : 1499 - 1502